Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD
Previous
Previous
Exclusive: Spot Bio launches with $40M to study mRNA therapy for muscular dystrophy
Next
Next